Modifier genes: Moving from pathogenesis to therapy.

Area of Science:

• Genetics and Molecular Biology
• Systems Biology
• Therapeutic Development

Background:

• Human diseases, even single-gene disorders, exhibit complex pathogenesis with variable patient outcomes.
• Lack of genotype-phenotype correlation highlights the role of modifier genes and biological networks.
• High costs of rare genetic disease medications pose challenges to patient access and compliance.

Purpose of the Study:

• To explore novel therapeutic approaches by leveraging knowledge of disease complexity and pathogenesis.
• To investigate the role of protective modifier genes and biological networks in disease variability.
• To identify potential therapeutic targets for rare genetic diseases.

Main Methods:

• Examined modifier genes and biological networks using vertebrate and invertebrate model organisms.
• Investigated protective modifiers (e.g., plastin 3 (PLS3), coronin 1C (CORO1C)) in spinal muscular atrophy (SMA) models.
• Utilized interactome analysis and antisense RNA strategies to modulate gene expression and rescue phenotypes.

Main Results:

• Identified PLS3 and CORO1C as protective modifiers in SMA, with their overexpression rescuing endocytosis.
• Demonstrated significant phenotypic variability in SMA influenced by SMN2 copy number.
• Showcased the potential of targeting protective modifiers and SMN2 for SMA therapy.

Conclusions:

• Functional understanding of biological complexity and repair mechanisms is crucial for developing new therapies.
• Protective modifiers offer a promising avenue for rescuing disease phenotypes in rare genetic disorders.
• Therapeutic strategies targeting modifier genes and networks can address unmet needs in genetic diseases like SMA, Duchenne muscular dystrophy, and glycerol kinase deficiency.